1. Home
  2. VERA vs PLUS Comparison

VERA vs PLUS Comparison

Compare VERA & PLUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VERA
  • PLUS
  • Stock Information
  • Founded
  • VERA 2016
  • PLUS 1990
  • Country
  • VERA United States
  • PLUS United States
  • Employees
  • VERA N/A
  • PLUS N/A
  • Industry
  • VERA Biotechnology: Pharmaceutical Preparations
  • PLUS Retail: Computer Software & Peripheral Equipment
  • Sector
  • VERA Health Care
  • PLUS Technology
  • Exchange
  • VERA Nasdaq
  • PLUS Nasdaq
  • Market Cap
  • VERA 2.5B
  • PLUS 2.6B
  • IPO Year
  • VERA 2021
  • PLUS 1996
  • Fundamental
  • Price
  • VERA $42.01
  • PLUS $96.76
  • Analyst Decision
  • VERA Strong Buy
  • PLUS Hold
  • Analyst Count
  • VERA 9
  • PLUS 1
  • Target Price
  • VERA $53.56
  • PLUS $90.00
  • AVG Volume (30 Days)
  • VERA 683.6K
  • PLUS 100.1K
  • Earning Date
  • VERA 11-07-2024
  • PLUS 11-05-2024
  • Dividend Yield
  • VERA N/A
  • PLUS N/A
  • EPS Growth
  • VERA N/A
  • PLUS N/A
  • EPS
  • VERA N/A
  • PLUS 4.08
  • Revenue
  • VERA N/A
  • PLUS $2,195,665,000.00
  • Revenue This Year
  • VERA N/A
  • PLUS $5.69
  • Revenue Next Year
  • VERA N/A
  • PLUS $4.68
  • P/E Ratio
  • VERA N/A
  • PLUS $24.00
  • Revenue Growth
  • VERA N/A
  • PLUS 0.56
  • 52 Week Low
  • VERA $9.68
  • PLUS $53.54
  • 52 Week High
  • VERA $50.78
  • PLUS $102.99
  • Technical
  • Relative Strength Index (RSI)
  • VERA 52.57
  • PLUS 52.65
  • Support Level
  • VERA $39.22
  • PLUS $96.35
  • Resistance Level
  • VERA $50.00
  • PLUS $99.25
  • Average True Range (ATR)
  • VERA 2.41
  • PLUS 2.09
  • MACD
  • VERA 0.24
  • PLUS -0.38
  • Stochastic Oscillator
  • VERA 28.53
  • PLUS 28.23

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

About PLUS ePlus inc.

ePlus Inc is a holding company. ePlus through its subsidiaries provides information technology solutions. The company's technology solutions enable organizations to optimize their IT environment and supply chain processes. It also provides consulting, professional and managed services, and complete lifecycle management services including flexible financing solutions. ePlus focuses on selling to medium and large enterprises in the United States and to customers in select international markets including the United Kingdom, the European Union, India, Singapore and Israel.

Share on Social Networks: